Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Drugs
Erschienen in: Drugs 4/2001

01.04.2001 | Leading Article

Potential of Microvascular Reperfusion with Adjunctive Pharmacological Intervention

Its Impact on Myocardial Perfusion and Functional Outcomes in Patients with Acute Myocardial Infarction

verfasst von: Dr Yoshiaki Taniyama, Hiroshi Ito, Ryuichi Morishita, Toshio Ogihara

Erschienen in: Drugs | Ausgabe 4/2001

Einloggen, um Zugang zu erhalten

Abstract

One of the major limitations of reperfusion therapy in acute myocardial infarction (AMI) is the presentation of no-reflow phenomenon. In 25 to 30% of patients with AMI, myocardial blood flow is occasionally profoundly reduced, even after coronary recanalisation, because of microvascular dysfunction - so-called no-reflow phenomenon. Patients with this phenomenon are regarded as a high risk group among patients with reperfused AMI.
Clinical studies using myocardial contrast echocardiography have demonstrated that intracoronary injection of calcium antagonists or potassium channel agonists in conjunction with coronary reperfusion can augment myocardial blood flow and that this was associated with better functional and clinical outcomes than with percutaneous transluminal coronary angioplasty alone. Thus, it is possible to prevent reperfusion injury and improve cardiac function using a adjunctive pharmacological intervention, either intravenously or by infusion directly into the coronary artery.
Literatur
1.
Hillis LD, Former S, Braunwald E. Risk stratification before thrombolytic therapy in patients with acute myocardial infarction. J Am Coll Cardiol 1990; 16: 313–5PubMedCrossRef
2.
Gruppo Italiano per lo Studio Delia Streptkinesi Nell E Infarct (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; I: 397–401
3.
Kennedy JW, Ritchie JL, Davis KB, et al. Western Washington randomized trial of intracoronary streptokinase in acute myocardial infarction. N Engl J Med 1983; 309: 1477–82PubMedCrossRef
4.
Bates ER, Krell MJ, Dean EN, et al. Demonstration of ‘no reflow’ phenomenon by digital coronary angiography. Am J Cardiol 1986; 57: 177–8PubMedCrossRef
5.
Jeremy RW, Links JM, Becker CC. Progressive failure of coronary flow during reperfusion of myocardial infarction: documentation of the no reflow phenomenon with positron emission tomography. J Am Coll Cardiol 1990; 16: 695–704PubMedCrossRef
6.
Feld H, Lichsten E, Schachter J, et al. Early and late angiographic findings of ‘no reflow’ phenomenon following direct angioplasty as primary treatment for acute myocardial infarction. Am Heart J 1992; 123(3): 782–4PubMedCrossRef
7.
Ito H, Tomooka T, Sakai N, et al. Lack of myocardial perfusion immediately after successful thrombolysis: predicator of poor recovery of left ventricular function in anterior myocardial infarction. Circulation 1992; 85: 1699–705PubMedCrossRef
8.
Ito H, Iwakura K, Oh H, et al. Temporal changes in myocardial perfusion patterns in patients with reperfused anterior wall myocardial infarction: their relation to myocardial viability. Circulation 1995; 91: 656–62PubMedCrossRef
9.
Ito H, Okamura A, Iwakura K, et al. Myocardial perfusion patterns related to thrombolysis in myocardial infarction grades after coronary angioplasty in patients with acute anterior wall myocardial infarction. Circulation 1996; 93: 1993–9PubMedCrossRef
10.
Ito H, Maruyama A, Iwakura K, et al. Clinical implications of ‘no reflow’ phenomenon: a predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. Circulation 1996; 93: 223–8PubMedCrossRef
11.
Lepper W, Hoffmann R, Kamp O, et al. Assessment of myocardial reperfusion by intravenous myocardial contrast echocardiography and coronary flow reserve after primary percutaneous transluminal coronary angiography in patients with acute myocardial infarction. Circulation 2000 May 23; 101(20): 2368–74PubMedCrossRef
12.
Stahl LD, Aversano TR, Becker LC. Selective enhancement of function of stunned myocardium by increased flow. Circulation 1986; 74: 843–51PubMedCrossRef
13.
Babbit DG, Virmani R, Forman MB. Intracoronary adenosine administrated after reperfusion limits vascular injury after prolonged ischemia in the canine model. Circulation 1989; 80: 1388–99CrossRef
14.
Mahaffey KW, Puma JA, Barbagelata A, et al. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomised, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. J Am Coll Cardiol 1999; 34(6): 1711–20PubMedCrossRef
15.
Marzilli M, Orsini E, Marraccini P, et al. Beneficial effect of intracoronary adenosine as adjunct to primary angioplasty in acute myocardial infarction. Circulation 2000; 101(18): 2154–9PubMedCrossRef
16.
Theroux P, Gregorie J, Chin C, et al. Intravenous diltiazem in acute myocardial infarction: diltiazem as adjunctive therapy to active (DATA) trial. J Am Coll Cardiol 1998; 32(3): 620–8PubMedCrossRef
17.
Piana RN, Paik GY, Mosucci M, et al. Incidence and treatment of ‘no reflow’ after percutaneous coronary intervention. Circulation 1994; 89: 2514–8PubMedCrossRef
18.
Taniyama Y, Ito H, Iwakura K, et al. Beneficial effect of intracoronary verapamil on microvascular salvage in patients with acute myocardial infarction. J Am Coll Cardiol 1997; 30: 1193–9PubMedCrossRef
19.
Kitakaze M, Minamino T, Node K, et al. Role of activation of ectopic 5’-nucleotidase in the cardioprotection mediated by opening K+ channel. Am J Physiol 1995; 26: 477–84
20.
Sakata Y, Kodama K, Komamura K, et al. Salutary effect of adjunctive intracoronary nicorandil administration on restoration of myocardial blood flow and functional improvement in patients with acute myocardial infarction. Am Heart J 1997; 133: 616–21PubMedCrossRef
21.
Ito H, Taniyama Y, Iwakura K, et al. Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction. J Am Coll Cardiol 1999; 33: 654–60PubMedCrossRef
22.
Villaneuva FS, Glasheen WP, Kaul S, et al. Characterization of spatial patterns of flow within the reperfused myocardium by myocardial contrast echocardiography: implication in determining extent of myocardial salvage. Circulation 1993; 88: 2596–606CrossRef
23.
Rawischer D, Levin TN, Cohen I, et al. Rapid reversal of noreflow using abciximab after coronary device intervention. Cathet Cardiovasc Diagn 1997; 41: 187–90CrossRef
24.
Brener SJ, Barr LA, Burchenal JE, et al. Effect of abciximab on the pattern of reperfusion in patients with acute myocardial infarction treated with primary angioplasty: RAPPORT investigators. ReoPro and primary PTCA organization and randomized trial. J Am Coll Cardiol 1999; 84(6): 728–30, A8
25.
Woods KL, Fletcher S, Roffe C, et al. Intravenous magnesium sulphate in suspected acute myocardial infarction: result of second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2). Lancet 1992; 339: 1553–9PubMedCrossRef
26.
Woods KL, Fletcher S. Long-term outcomes after intravenous magnesium sulphate in suspected acute myocardial infarction: the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2). Lancet 1994; 343: 816–9PubMedCrossRef
27.
ISIS collaborate groups. ISIS-4: randomized study of intravenous magnesium in over 50,000 patients with suspected acute myocardial infarction. Lancet 1995; 345: 669–85CrossRef
28.
Herog WR, Schoolbag ML, MacMurdy K, et al. Timing of magnesium therapy affects experimental infarct size. Circulation 1995; 92: 2622–6CrossRef
29.
Forman MB, Perry JM, Wilson BH, et al. Demonstration of myocardial reperfusion injury in humans: result of a pilot study utilizing acute coronary angioplasty with perfluorochemical emulsion in the treatment of myocardial reperfusion injury. Am Heart J 1992; 124: 1347–57PubMedCrossRef
30.
Buerke M, Rupprecht HJ, vom Dahl J, et al. Sodium-hydrogen exchange inhibition: novel strategy to prevent myocardial injury following ischemia and reperfusion. Am J Cardiol 1999; 83(10A): 19G–22GPubMedCrossRef
31.
Rupprecht HJ, Dahl JV, Terres W, et al. Cardioprotective effects of the Na (+9)/H (+) exchange inhibitor cariporide in patients with acute anterior myocardial infarction undergoing direct PTCA. Circulation 2000; 101(25): 2902–8PubMedCrossRef
Metadaten
Titel
Potential of Microvascular Reperfusion with Adjunctive Pharmacological Intervention
Its Impact on Myocardial Perfusion and Functional Outcomes in Patients with Acute Myocardial Infarction
verfasst von
Dr Yoshiaki Taniyama
Hiroshi Ito
Ryuichi Morishita
Toshio Ogihara
Publikationsdatum
01.04.2001
Verlag
Springer International Publishing
Erschienen in
Drugs / Ausgabe 4/2001
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI
https://doi.org/10.2165/00003495-200161040-00002

Weitere Artikel der Ausgabe 4/2001

Drugs 4/2001 Zur Ausgabe

Current Opinion

β-Blockers in the Management of Hypertension in Patients with Type 2 Diabetes Mellitus

Therapy in Practice

Managing Cancer-Related Anorexia/Cachexia

Adis Drug Evaluation

Linezolid

Adis New Drug Profile

Argatroban

Adis New Drug Profile

Argatroban

Review Article

Review of Macrolides and Ketolides